Published: Sep, 2017
The global primary immunodeficiency diseases (PIDD) market is consolidated with CSL Behring LLC and Grifols S.A. holding a collective share of 60.5% in 2014, states Transparency Market Research (TMR) in its latest report. Other leading players within the market are Octapharma AG and Baxter International, Inc. These companies are primarily capitalizing on the growing incidences of immunodeficiency diseases and investing extensively on the research and development so as to come up with new and effective treatment options. The growing R&D investments by leading market players are helping them maintain their strong foothold in the primary immunodeficiency diseases market. In addition to this, increased funding for pharmaceutical and biopharmaceutical research will encourage market players to continue on their mission to develop effective treatment solutions.
According to the report by TMR, global primary immunodeficiency diseases market will be worth US$7.5 bn by the end of 2023. On the basis of geography, Europe and North America are leading. Asia Pacific will emerge as an attractive market for primary immunodeficiency diseases. On the basis of treatment, the immunoglobulin replacement segment is predicted to witness an exponential rise in the years to come. There will also be a rise in the demand for stem cell and gene therapy for PIDD treatment.
Growing Awareness Regarding PIDD to Drive Demand
The global primary immunodeficiency diseases market is driven by government approvals and support. The awareness created about PIDD by various government and private organizations will also aid the growth of this market. The demand will witness a positive rise in both developed and developing countries. Unmet medical needs in emerging nations will act as growth opportunity for primary immunodeficiency diseases market, states TMR. Recently many policies have been undertaken by governments across developing countries which work in the favor of this market’s growth. Also, favorable health trends in Asia Pacific will boost the growth of this market.
Undetected Cases due to Inadequate Provision for Diagnosis of PIDD to Pose a Key Challenge
Inadequate and unfavorable reimbursement policies in many nations will hamper the growth of the global primary immunodeficiency diseases market. The absence of adequate provision for diagnosis of PIDD among newborns will restrict the growth of this market. Many cases go undetected in developing nations. “Of the 10 mn people who actually suffer from primary immunodeficiency diseases, thousands of adult cases also go undiagnosed, acting as a major challenge for the growth of this market,” states a TMR analyst.
This review is based on information published by TMR in a report, titled “Primary Immunodeficiency Diseases Market (Disease - Antibody Deficiency (Agammaglobulinaemia ((X-Linked and Autosomal Recessive), Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency) Cellular Immunodeficiency (Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome) Innate Immune Disorders (Complement Deficiencies, Hyper IgE Syndrome); Test (Blood Test, Prenatal Test); Treatment (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy))- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”
The global primary immunodeficiency diseases market is segmented as follows:
Global Primary Immunodeficiency Diseases Market, by Disease
- Antibody Deficiency
- Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
- Common Variable Immune Deficiency
- Selective IgA Deficiency
- IgG Subclass Deficiency
- Cellular Immunodeficiency
- Ataxia Telangiectasia
- Hyper IgM Syndromes
- Wiskott-Aldrich Syndrome
- DiGeorge Syndrome
- Innate Immune Disorders
- Complement Deficiencies
- Hyper IgE Syndrome
Global Primary Immunodeficiency Diseases Market, by Test
- Blood Test
- Prenatal Testing
Global Primary Immunodeficiency Diseases Market, by Treatment
- Immunoglobulin Replacement Therapy
- Antibiotic Therapy
- Stem cell and Gene Therapy
Global Primary Immunodeficiency Diseases Market, by Geography
- North America
- Latin America
- Asia Pacific
- Rest of the World
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453